| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 14
| Issue : 10 | Page : 583-586 |
|
|
The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis
Turkan Ozturk Topcu1, Halil Kavgaci1, Meral Gunaldi2, Hakan Kocoglu3, Murat Akyol4, Ahmet Mentese5, Serap Ozer Yaman5, Asim Orem5, Feyyaz Ozdemir1, Fazil Aydin1
1 Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey
2 Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
3 Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
4 Department of Medical Oncology, Manisa Public Hospital, Manisa, Turkey
5 Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey
Correspondence Address:
Hakan Kocoglu
Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Zuhuratbaba, Tevfik Saglam Street, No. 11, 34147 Bakirkoy, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.176425
|
|
|
Objective: Studies have investigated expression status of galectin-3 (Gal-3), but very little is known about the importance of circulating Gal-3 in patients with breast cancer (BC). The purpose of the study was to investigate the clinical significance and potential diagnostic value of plasma Gal-3 levels in patients with BC.
Materials and Methods: Fifty-two patients with BC and 35 age-matched healthy controls were enrolled. Levels of Gal-3 were investigated in BC patients and healthy controls. Gal-3 levels were determined using ELISA method.
Results: Serum Gal-3 levels were significantly higher in BC patients than in controls (P = 0.002). Gal-3 levels did not significantly differ according to patients' statuses of lymph node involvement, hormone receptor, lymphovascular invasion, e-cadherin, menopausal, stage, serum hemostatic markers (prothrombin time, partial thromboplastin time, and international normalized ratio), platelet counts, mean platelet volume, lactate dehydrogenase, carcinoembryonic antigen, and carbohydrate antigen 15-3 values (P > 0.05 for all). A cut-off value of Gal-3 to predict BC was determined at ≥3.17 ng/ml with a sensitivity of 75.0%, a specificity of 65.71%, a positive and negative predictive values of 76.5 and 63.9%, respectively (area under the curve: 0.705 [95% confidence interval, 0.598–0.798], P = 0.0002).
Conclusion: Serum Gal-3 levels were significantly higher in BC patients and did not significantly differ according to clinical and tumoral characteristics of patients. Furthermore, there was no difference in Gal-3 levels between BC patients with and without metastatic disease. Serum Gal-3 levels can be used as an adjunct to other diagnostic or screening tests for BC regardless of clinical and tumoral characteristics of patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
